Orionis Biosciences Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Waltham MA US

Primary Industry

Biotechnology

About

Based in Massachusetts, US, and founded in 2015, Orionis Biosciences Inc. operates as a life sciences company working on drug discovery and tunable molecular design of novel therapeutic drug modalities. In October 2022, Orionis Biosciences raised USD 55 million in venture funding from Cormorant Asset Management and returning investor Novartis. As of October 2022, the company is led by its CEO Nikolai Kley. Orionis Biosciences Inc. developing a diverse spectrum of small molecule molecular glues using its Allo-Glue™ platform, which harnesses a genome-scale approach for the discovery and rational design of molecular glues in order to reach previously intractable targets; A-Kine™ designed to trigger anti-tumor immune responses even in cold tumors that lack prevalent immune involvement and are refractory to checkpoint inhibitor therapies. The company plans to use venture funding to invest in R&D, grow its pipeline of products and advance its lead cancer immunotherapy programs into clinical trials.

Current Investors

Cormorant Asset Management, Novartis, Excel Venture Management

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development, Medical Software

Website

http://www.orionisbio.com

Verticals

HealthTech

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.